Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings

Seminars in Nuclear Medicine

Volumn 32, Issue 2, 2002, Pages 133-140

  De Jong, Marion ^a,b,c,d   Valkema, Roelf ^a,b,c,d   Jamar, Francois ^a,b,c,d   Kvols, Larry K ^a,b,c,d   Kwekkeboom, Dik J ^a,b,c,d   Breeman, Wout A P ^a,b,c,d   Bakker, Willem H ^a,b,c,d   Smith, Chuck ^a,b,c,d   Pauwels, Stanislas ^a,b,c,d   Krenning, Eric P ^a,b,c,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTATE[3 TYROSINE]; OCTREOTATE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; OCTREOTIDE[3 TYROSINE]; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; ISOTOPE LABELING; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS CANCER; RADIOISOTOPE THERAPY;

EID: 0036226273     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2002.31027     Document Type: Article

References (35)

1. Comparison of (111) In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
2. 0]octreotide in patients
3. 1]octreotide. A case history
4. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues
5. 1]-octreotide
6. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver
7. Yttrium-90-labelled somatostatin-analogue for cancer treatment
8. Yttrium-90 DOTATOC: First clinical results
9. 3-octreotide: Preliminary report in cancer patients
10. 3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours
11. Targeted radiotherapy with 90Y-SMT487 (OctreoTher): A phase I study
12. 3-octreotate in a rat tumor model
13. 3] octreotate for somatostatin receptor-targeted radionuclide therapy
14. 3-octreotate in patients with somatostatin receptor positive tumors: Preliminary results
15. The somatostatin receptor family
16. Somatostatin and its receptor family
17. Somatostatin receptors: Present knowledge and future directions
18. 3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy
19. 1-octreotide
20. Internalisation of isotope-coupled somatostatin analogues
21. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes
22. Progressive nuclear translocation of somatostatin analogs
23. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy
24. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
25. 3]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size
26. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer
27. TM) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study
28. 3-octreotide
29. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
30. 3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
31. Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: Tumour size versus curability
32. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides
33. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy
34. RGD-DTPA-OCTREOTATE, an analogue for tumour imaging and radionuclide therapy
35. Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review